The European Commission (Commission) cleared the acquisition of US Company Barr Pharmaceuticals (Barr) by the Israeli company, Teva Pharmaceutical Industries (Teva), on 19 December 2008, subject to conditions. Both companies specialise in the development, production and marketing of generic medicines. The main areas of overlap between the parties’ respective businesses were in relation to certain cancer drugs and prescription vitamins in certain Eastern European markets where their aggregate market shares would be quite significant. This gave rise to concern that the removal of Barr as a competitor to Teva for certain cancer drugs might give rise to increased prices for hospitals and patients. To meet these concerns, Teva offered to divest certain cancer drugs and/or vitamin products in the Czech Republic, Hungary, Poland, the Slovak Republic and Slovenia. The Commission concluded that the divestments would alleviate the competition concerns and approved the deal.